GPT and metabolic dysfunction-associated steatotic liver disease: T2DM patients with high ALT (>12 IU/L) had significantly more than two times the risk (aOR = 2.335, 95% CI: 1.096–5.062) of NAFLD compared to T2DM patients with normal ALT (<12 IU/L).